The MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI)
|ORDER ASSESSMENT TOOLS|
MD Anderson Symptom Inventory (MDASI) modules augment the 19 core MDASI symptom and interference items with additional items identified as unique to a particular patient population. MDASI modules may be disease-specific, disease-site-specific, or treatment-specific.
The MDASI gastrointestinal cancer module (MDASI-GI) is a site-specific module. Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-GI also assesses 5 gastrointestinal cancer-specific symptom items: constipation, diarrhea/watery stools, difficulty swallowing, change in taste, and feeling bloated.
- Purpose: To assess the severity of multiple gastrointestinal cancer-related symptoms and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by gastrointestinal cancer and its treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
- Time required: Five minutes
- Scoring: Please see the MDASI User's Guide
- Reliability: Cronbach alpha reliability ranges from 0.80 to 0.87
MDASI-GI Language Versions
The MDASI-GI is available in the languages shown below. Click on a linked language to view a sample in PDF format.
|Psychometrically and Linguistically Validated||Linguistically Validated|
Future Validation Studies: We would like to collaborate with other investigators to develop and validate new language versions of the MDASI-GI. Contact us for more information. NOTE: The MDASI-GI may not be modified or translated into another language without express written consent (see Notice of Copyright below).
To Order the MDASI-GI
|Type of Use||First Language Version (Per Project)||Additional Language Versions (Per Project)|
|Non-funded academic research||No charge||No charge|
|Individual clinical practice||No charge||No charge|
|Funded academic research||$300||$150|
The MDASI-GI will be e-mailed to you as a PDF file within 7 to 10 business days. If your request is urgent or the language version you seek is not shown, contact us to make special arrangements:
Department of Symptom Research
Attn: Assessment Tools
The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 1450
Houston, Texas 77030
If applicable, an invoice will be e-mailed to you. Reference the invoice number on your payment and include on the memo line, "MD Anderson Assessment Tool Distribution."
The M. D. Anderson Symptom Inventory (MDASI) copyright is held by The University of Texas MD Anderson Cancer Center and administered by the MDASI's developer, Charles S. Cleeland, PhD. The copyright applies to the MDASI, its modules, and all its derivatives in any language.
The MDASI-GI may not be used or reproduced without permission from Charles S. Cleeland, PhD, or his designee. Fees for use may apply (see above).
The MDASI and its modules may not be modified or translated into another language without the express written consent of the copyright holder. Failure to comply may result in legal action. Contact us via e-mail at firstname.lastname@example.org or at the address shown above to obtain permission to alter or translate the instrument.
Wang XS, Williams LA, Eng C, Mendoza TR, Shah NA, Kirkendoll KJ, Shah PK, Trask PC, Palos GR, Cleeland CS. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer 116(8): 2053-2063, 2010.
Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle M, Morrissey M, & Engstrom MC. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer 2000; 89:1634-1646.
Janjan NA, Wang XS, Mendoza TR, Zhang Y, Das P, Crane C, Delclos M, Krishnan S, Cleeland CS. Utility of the M. D. Anderson Symptom Inventory (MDASI) for symptom evaluation during chemoradiation in patients with gastrointestinal malignancies [abstract]. American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, Jun 1-5, 2007. J Clin Oncol 25(18 Suppl), 2007; 6613.
Symptom Research hosts national colloquium on developing strategies for reducing cancer treatment-related toxicities and symptoms. Read more...
Announcing the publication of Cancer Symptom Science, an interdisciplinary, first-of-its-kind compilation of research on the mechanisms underlying the expression of cancer-related symptoms. Read more...
Old Drugs, New Possibilities (Conquest, Fall 2008)
Symptom Research Awarded NIH P01 Grant (Division of Internal Medicine Newsletter, Summer 2008)
Symptom Research and Psychometrics (Network, Summer 2008)